TME Pharma N.V. has successfully completed its August financing round, securing €500,000 in additional funding that brings the clinical-stage biotechnology company's total cash position to €2.35 million. The transaction, announced on August 25th and completed on August 28th, follows an earlier €1.7 million raise in May 2025, demonstrating continued investor confidence in the company's novel therapeutic pipeline.
Strategic Restructuring Drives Cost Efficiency
Under the leadership of new CEO Diede van den Ouden, who joined the company in June 2025, TME Pharma is implementing a comprehensive strategic restructuring focused on cost optimization. The lower cost-base model positions the company to more effectively attract development partners for its cancer and eye disease programs while maximizing the value of its current funding.
Van den Ouden, who personally contributed €500,000 to the May funding round, continues to implement the company's treasury investment strategy to balance risk and return for optimal shareholder outcomes. The company is evaluating cryptocurrency and crypto-related investment opportunities as part of this strategy, though it currently maintains no exposure to digital assets.
Lead Programs Target High Unmet Medical Needs
TME Pharma's pipeline centers on two lead compounds designed to act on the tumor microenvironment and cancer immunity cycle by breaking tumor protection barriers and blocking tumor repair mechanisms.
NOX-A12 Advances in Glioblastoma Treatment
NOX-A12 (olaptesed pegol), an anti-CXCL12 L-RNA aptamer, represents the company's most advanced program. The compound has received FDA Fast Track Designation for use in combination with radiotherapy and bevacizumab in treating glioblastoma, an aggressive adult brain cancer. Additionally, NOX-A12 combined with radiotherapy has secured orphan drug designation for glioblastoma in the United States and glioma in Europe.
The ongoing GLORIA study (NCT04121455) is evaluating NOX-A12 in a dose-escalation Phase 1/2 trial. The study focuses on newly-diagnosed brain cancer patients with unmethylated MGMT promoter who will not benefit from standard chemotherapy. Both the US FDA and German BfArM have approved the design of a randomized Phase 2 trial in glioblastoma, marking significant regulatory progress for the program.
The GLORIA trial's expansion arm further evaluates the safety and efficacy of NOX-A12 when combined with radiotherapy and bevacizumab in first-line partially resected or unresected glioblastoma patients.
NOX-E36 Targets Ophthalmic Diseases
The company's second lead asset, NOX-E36 (emapticap pegol), is an L-RNA aptamer that inhibits CCL2 and related chemokines. This compound is being evaluated for ophthalmic diseases where there is high demand for well-tolerated therapies with anti-fibrotic effects.
Expanding Pipeline in Pancreatic Cancer
TME Pharma is also advancing the planned OPTIMUS study (NCT04901741), an open-label two-arm Phase 2 trial of NOX-A12 combined with pembrolizumab and either nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nab-paclitaxel in microsatellite-stable metastatic pancreatic cancer patients.
Financial Strategy and Future Outlook
The company's strategic restructuring encompasses multiple financial initiatives beyond traditional fundraising. These include pursuing stable, cash-generating business opportunities to achieve positive operational cash flow, leveraging tax loss carry forwards, and establishing a crypto brokerage account for potential digital asset exposure.
TME Pharma maintains high expectations for both its NOX-A12 and NOX-E36 programs as it continues to advance these novel therapeutic approaches. The company has committed to keeping markets informed of ongoing progress as it works to unlock the value of its lead compounds through the improved cost-efficient operational model.
